Serum MIP-1α correlates with survival and bone resorption markers, which suggests that MIP-1α possibly contributes to MBD pathogenesis and tumor growth as reflected by its effect on survival [4,5]. The gene discussed is CCL3; the disease is Marchiafava-Bignami disease.